ReviewFrontiers in aging neuroscience2026
Global research trends and hotspots in blood-based biomarkers for Alzheimer's disease: a bibliometric analysis.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Blood-based biomarkers (BBMs) are rapidly reshaping the diagnostic and translational landscape of Alzheimer's disease (AD), offering a scalable alternative to cerebrospinal fluid (CSF) assays and positron emission tomography (PET). This paper aims to conduct bibliometric analysis on the hotspots and trends in this field. Methods: Publications addressing AD-related blood/plasma/serum biomarkers from 1 January 2011 to 29 November 2025 were retrieved from the Web of Science Core Collection (WoSCC) and Scopus. Only English-language articles and reviews were included. VOSviewer, CiteSpace, and the R package bibliometrix were used to evaluate publication trends, collaboration networks (countries, institutions, authors), co-cited journals and references, and keyword evolution. Results: A total of 1,771 publications with 53,568 citations were included. Annual output rose steadily and accelerated after 2018, while 2025 records covered approximately the first 11 months of the year. The USA (795 publications) and China (478) were the most productive countries, whereas the UK and Sweden showed strong citation impact and collaboration intensity. The University of Gothenburg (263) and Sahlgrenska University Hospital (237) were the leading institutions. Henrik Zetterberg (218) and Kaj Blennow (185) were the most prolific authors. Co-citation analysis identified the NIA-AA biological research framework and validation studies of plasma amyloid-beta (Aβ) and plasma phosphorylated tau (p-tau) as the intellectual base. Keyword and burst analyses indicated a clear shift from early themes (e.g., proteomics and oxidative stress) toward clinically oriented topics, including plasma p-tau217/p-tau181, diagnostic performance, and implementation recommendations. Conclusion: Research on AD BBMs has entered a phase of rapid growth and clinical translation. Plasma phosphorylated tau (especially p-tau217) is the leading biomarker for detecting AD-specific pathology. Plasma Aβ ratios play a supportive role in amyloid triage, while neurodegeneration (NfL) and astroglial (GFAP) markers provide complementary information for prognosis and monitoring. Future priorities include real-world implementation, assay standardization, and integration of multi-marker panels into biological diagnostic/staging frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.